Market research
1498.HK PuraPharm Corporation Limited
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 150M
- P/E ratio
- Not available
- Analyst target
- 4.2
- Dividend yield
- Not available
- Beta
- 0.2
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KYG7306Y1044
- Market cap
- 150M
- P/E ratio
- Not available
- Analyst target
- 4.2
- Dividend yield
- Not available
- Beta
- 0.2
About
About PuraPharm Corporation Limited
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provides Chinese medicine services and CCMG products. In addition, the company engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of new products and bio-based polymeric materials. Further, It operates an online platform. PuraPharm Corporation Limited was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1498.HK discussion.
5 years, 5 months ago
PuraPharm Corporation Limited is currently in a long term downtrend where the price is trading 1.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.3.
PuraPharm Corporation Limited's total revenue sank by 22.6% to $280M since the same quarter in the previous year.
Its net income has increased by 106.3% to $11M since the same quarter in the previous year.
Finally, its free cash flow grew by 102.4% to $1M since the same quarter in the previous year.
Based on the above factors, PuraPharm Corporation Limited gets an overall score of 3/5.